REAGILA: An Atypical Antipsychotic Used in the Treatment of Schizophrenia and Manic or Mixed Episodes of Bipolar Disorder – Drug Insights and Market Forecasts to 2032

DUBLIN, Dec. 8, 2023 /PRNewswire/ — The “REAGILA Drug Insight and Market Forecast – 2032” drug pipelines has been added to ResearchAndMarkets.com’s offering. This report provides comprehensive insights about REAGILA for schizophrenia in the seven major markets. A detailed picture of the…